NASDAQ: PHIOPhio Pharmaceuticals Corp Stock
$0.64-0.01 (-1.54%)
Updated Apr 18, 2024
PHIO Price
$0.64
Fair Value Price
N/A
Market Cap
$2.93M
52 Week Low
$0.50
52 Week High
$6.85
P/E
-0.12x
P/B
0.38x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.83M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$11M
Beta
0.6
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PHIO Overview
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PHIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHIO is good value based on its book value relative to its share price (0.38x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
PHIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PHIO due diligence checks available for Premium users.
Be the first to know about important PHIO news, forecast changes, insider trades & much more!
PHIO News
Valuation
PHIO fair value
Fair Value of PHIO stock based on Discounted Cash Flow (DCF)
Price
$0.64
Fair Value
$0.00
Overvalued by
15,671.55%
PHIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PHIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
15.68x
Market
41.33x
PHIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.38x
Industry
5.76x
PHIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PHIO's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
PHIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.4M
Liabilities
$1.6M
Debt to equity
0.21
PHIO's short-term assets ($9.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHIO's short-term assets ($9.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PHIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
$0.0
Financing
$2.4M
PHIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PHIO vs Biotech Stocks
Phio Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.